{"disease":{"id":"partial-epilepsy","name":"partial epilepsy"},"drugs":{"marketed":[{"drug_id":"keppra","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Keppra","company_name":"Masonic Cancer Center, University of Minnesota","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"bat","indication_name":"Treatment of partial-onset seizures with and without secondary generalization in patients 12 years of age and older with epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"lacosamide","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vimpat","generic_name":"lacosamide","company_name":"UCB","drug_phase":"marketed","molecular_target":"Dihydropyrimidinase-related protein 2, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"clorazepate","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tranxene","generic_name":"clorazepate","company_name":"Ajenat Pharms","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"Benzodiazepine","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"levetiracetam","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keppra","generic_name":"levetiracetam","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Synaptic vesicle protein SV2A","drug_class":"Antiepileptic agent","quality_score":10,"revenue":null,"mechanism":"Levetiracetam binds to synaptic vesicle protein SV2A, potentially regulating vesicle exocytosis."},{"drug_id":"gabapentin","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"gabapentin","company_name":"Generic (originally Parke-Davis/Pfizer)","drug_phase":"marketed","molecular_target":"Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor","drug_class":"Gabapentinoid (anticonvulsant/neuropathic pain agent)","quality_score":10,"revenue":null,"mechanism":"Binds the alpha-2-delta subunit of voltage-gated calcium channels, modulating neurotransmitter release to treat neuropathic pain and seizures."},{"drug_id":"zonegran","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zonegran","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gabapentine","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"gabapentine","company_name":"Dominik Irnich","drug_phase":"marketed","molecular_target":"Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"retigabine","indication_name":"Partial Epilepsy Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Retigabine","company_name":"Bausch Health Americas, Inc.","drug_phase":"discontinued","molecular_target":"Potassium voltage-gated channel subfamily KQT member 2, Potassium voltage-gated channel subfamily KQT member 3, Potassium voltage-gated channel subfamily KQT member 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":10,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02535091","title":"Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1345,"lead_sponsor_name":"SK Life Science, Inc.","has_results":true},{"nct_id":"NCT03478852","title":"Investigating Epilepsy: Screening and Evaluation","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT00988429","title":"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":653,"lead_sponsor_name":"Bial - Portela C S.A.","has_results":true},{"nct_id":"NCT01463306","title":"A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":605,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT03083665","title":"A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":449,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT01866111","title":"A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":437,"lead_sponsor_name":"SK Life Science, Inc.","has_results":true},{"nct_id":"NCT00988156","title":"Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":304,"lead_sponsor_name":"Bial - Portela C S.A.","has_results":true},{"nct_id":"NCT01273129","title":"Surgery as a Treatment for Medically Intractable Epilepsy","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT01397968","title":"Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"SK Life Science, Inc.","has_results":true},{"nct_id":"NCT03250377","title":"A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":207,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT03836924","title":"A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Eisai Pharmaceuticals India Pvt. Ltd","has_results":false},{"nct_id":"NCT00706160","title":"Language Mapping in Patients With Epilepsy","phase":"","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT06960811","title":"Epileptic Psychoses and Their Link With Ictal Emotions and Consciousness","phase":"","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT00001932","title":"Serotonin Receptors in Seizure Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT02076698","title":"Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT03446664","title":"Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"LivaNova","has_results":false},{"nct_id":"NCT06967012","title":"A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Affiliated Hospital of Nantong University","has_results":false},{"nct_id":"NCT04903314","title":"Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"SK Life Science, Inc.","has_results":false},{"nct_id":"NCT01281956","title":"PRX-00023 Therapy in Localization-Related Epilepsy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":true},{"nct_id":"NCT03685630","title":"A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":false},{"nct_id":"NCT04839601","title":"RNS System RESPONSE Study","phase":"NA","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"NeuroPace","has_results":false},{"nct_id":"NCT01496612","title":"Buspirone Therapy for Localized Epilepsy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":true},{"nct_id":"NCT05015868","title":"Contribution of Genetics, Non-invasive Methods and Neuropsychology in Focal Cryptogenic Epilepsies","phase":"NA","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"IRCCS Eugenio Medea","has_results":false},{"nct_id":"NCT04513860","title":"Cenobamate Expanded Access Program (EAP)","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"SK Life Science, Inc.","has_results":false}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}